Elanco Animal Health Inc (ELAN) stock
ELANNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/30129% above fair value
$26.70+0.85 (+3.29%)
Close on Nov 18, 2026Market cap $13.34BP/E –Yield –
Elanco Animal Health operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Elanco Animal Health's operating cash flow for the twelve months ending Jun 30, 2026 was $617.00M, up 7.9% year over year. For fiscal 2025 it was $560.00M, up 3.5% from the year before. The highest annual figure on record is $560.00M in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $560.00M | +3.5% |
| FY2024 | Dec 31, 2024 | $541.00M | +99.6% |
| FY2023 | Dec 31, 2023 | $271.00M | -40.0% |
| FY2022 | Dec 31, 2022 | $452.00M | -6.4% |
| FY2021 | Dec 31, 2021 | $483.00M | – |
| FY2020 | Dec 31, 2020 | -$41.00M | -118.3% |
| FY2019 | Dec 31, 2019 | $224.00M | -54.0% |
| FY2018 | Dec 31, 2018 | $487.30M | +180.4% |
| FY2017 | Dec 31, 2017 | $173.80M | +11.5% |
| FY2016 | Dec 31, 2016 | $155.90M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $277.00M | +16.9% |
| Q1 FY2026 | Mar 31, 2026 | $13.00M | – |
| Q4 FY2025 | Dec 31, 2025 | $108.00M | -39.0% |
| Q3 FY2025 | Sep 30, 2025 | $219.00M | +35.2% |
| Q2 FY2025 | Jun 30, 2025 | $237.00M | +18.5% |
| Q1 FY2025 | Mar 31, 2025 | -$4.00M | -300.0% |
| Q4 FY2024 | Dec 31, 2024 | $177.00M | +12.7% |
| Q3 FY2024 | Sep 30, 2024 | $162.00M | -18.2% |
| Q2 FY2024 | Jun 30, 2024 | $200.00M | +227.9% |
| Q1 FY2024 | Mar 31, 2024 | $2.00M | – |
| Q4 FY2023 | Dec 31, 2023 | $157.00M | +1107.7% |
| Q3 FY2023 | Sep 30, 2023 | $198.00M | +4.8% |
| Q2 FY2023 | Jun 30, 2023 | $61.00M | -80.4% |
| Q1 FY2023 | Mar 31, 2023 | -$145.00M | – |
| Q4 FY2022 | Dec 31, 2022 | $13.00M | -94.2% |
| Q3 FY2022 | Sep 30, 2022 | $189.00M | +112.4% |
| Q2 FY2022 | Jun 30, 2022 | $312.00M | +109.4% |
| Q1 FY2022 | Mar 31, 2022 | -$62.00M | -381.8% |
| Q4 FY2021 | Dec 31, 2021 | $223.00M | – |
| Q3 FY2021 | Sep 30, 2021 | $89.00M | – |
| Q2 FY2021 | Jun 30, 2021 | $149.00M | -6.9% |
| Q1 FY2021 | Mar 31, 2021 | $22.00M | +450.0% |
| Q4 FY2020 | Dec 31, 2020 | -$93.00M | -173.7% |
| Q3 FY2020 | Sep 30, 2020 | -$112.00M | -382.8% |
| Q2 FY2020 | Jun 30, 2020 | $160.00M | +219.4% |
| Q1 FY2020 | Mar 31, 2020 | $4.00M | -50.6% |
| Q4 FY2019 | Dec 31, 2019 | $126.20M | -9.5% |
| Q3 FY2019 | Sep 30, 2019 | $39.60M | -75.8% |
| Q2 FY2019 | Jun 30, 2019 | $50.10M | -63.4% |
| Q1 FY2019 | Mar 31, 2019 | $8.10M | -82.8% |
| Q4 FY2018 | Dec 31, 2018 | $139.50M | +1982.1% |
| Q3 FY2018 | Sep 30, 2018 | $163.90M | – |
| Q2 FY2018 | Jun 30, 2018 | $136.90M | – |
| Q1 FY2018 | Mar 31, 2018 | $47.00M | – |
| Q4 FY2017 | Dec 31, 2017 | $6.70M | – |
See a number that looks wrong?